Search
for
Sort by
Research 61–90 of 1000+
- withdrawn
- Efficacy and safety of oral finasteride <i>versus</i> dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- A phase 2a trial of brepocitinib for cicatricial alopecia
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
- Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma
- Risk assessment of the top 60 drugs for drug-related sexual dysfunction: a disproportion analysis from the Food and Drug Administration adverse event reporting system
- Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis
- The nocebo effect: A clinicians guide
- Evaluación de la seguridad de minoxidil oral a dosis bajas en el tratamiento de la alopecia
- Safety and Effectiveness of a Novel Hyaluronic Acid Gel for Lip Augmentation
- Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology
- The efficacy and safety of BM-PHA for the correction of nasolabial folds: a multicenter, randomized, double-blind, split-face clinical trial
- Minoxidil oral en alopecia androgénica: estudio retrospectivo acerca de su seguridad en práctica clínica real
- Abstracts Pt.30
- Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- Combination Therapy with Baricitinib and Narrowband Ultraviolet B for Active Non-Segmental Vitiligo: A Retrospective Controlled Study
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Efectos de la disminución de los depósitos tisulares de hierro sobre los factores de riesgo cardiovascular en pacientes con hiperandrogenismo ovárico funcional
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- The Requirement to Monitor Low-dose Oral Minoxidil in the Management of Hair Loss
- Direct-Acting Vasodilators
- 53274 Real-world experience of efficacy and safety of baricitinib in Korean patients with severe alopecia areata
- 54022 Pooled Safety Assessments from the Multinational Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials of Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata
- Local Pharmacokinetics and Tolerability of Topically‐Applied Bimatoprost to the Scalp of Male Patients With Androgenetic Alopecia